RG
LAB icon

Redmile Group’s Standard BioTools LAB Stock Holding History

Redmile Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-411,631
Closed -$729K – 65
2024
Q2 		$729K Hold
411,631
– – 0.04% 60
2024
Q1 		$1.12M Buy
+411,631
New +$994K 0.04% 75
2016
Q1 		– Sell
-32,561
Closed -$352K – 53
2015
Q4 		$352K Buy
32,561
+7,978
+32% +$78.3K 0.03% 50
2015
Q3 		$199K Sell
24,583
-323,654
-93% -$5.09M 0.02% 57
2015
Q2 		$8.43M Sell
348,237
-214,200
-38% -$6.76M 0.69% 40
2015
Q1 		$23.7M Sell
562,437
-48,005
-8% -$1.9M 2.13% 14
2014
Q4 		$20.6M Buy
610,442
+50,820
+9% +$1.44M 2.24% 15
2014
Q3 		$13.7M Buy
559,622
+167,082
+43% +$4.7M 1.58% 28
2014
Q2 		$11.5M Buy
+392,540
New +$12.6M 1.4% 32

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Redmile Group's LAB Position: Q3 2024 in Review

Redmile Group sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 411,631 shares — an estimated $729K sold.

Redmile Group first reported a position in LAB in Q2 2014 and held it in 9 quarters. The position peaked at $23.7M in Q1 2015. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • Redmile Group reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • Redmile Group sold 411,631 Standard BioTools shares in Q3 2024, an estimated $729K.
  • Redmile Group first reported a position in Standard BioTools in Q2 2014 and held it in 9 quarters.
  • Redmile Group's Standard BioTools position peaked at $23.7M in Q1 2015.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.